Immunovant, Inc. 8-K

What Happened

• Immunovant, Inc. announced its financial results for the fourth quarter and fiscal year ended March 31, 2026 via a press release dated May 20, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8‑K filed the same day (Accession No. 0001764013-26-000062). The filing was signed by CFO Tiago Girao.

Key Details

• Event: Company announced quarterly and fiscal year financial results (Q4 and FY ended March 31, 2026).
• Filing date: May 20, 2026 (Form 8‑K).
• Exhibit: Press release furnished as Exhibit 99.1; Interactive XBRL cover page included as Exhibit 104.
• Signature: Form 8‑K signed by Chief Financial Officer Tiago Girao.

Why It Matters

• Earnings and financial-condition announcements provide the latest information on revenue, expenses, and overall performance that can affect valuation and trading in Immunovant stock.
• The press release (Exhibit 99.1) is the primary source of the company’s communicated results; investors should read it and look for follow-up filings (quarterly or annual reports) for full financial statements and detailed metrics.
• This Form 8‑K confirms the timing and availability of those results and that the company has officially disclosed them to the market.